Piramal Pharma's consolidated net profit for the second quarter ended September has increased significantly, rising over four-fold to Rs 23 crore from Rs 5 crore in the same period last fiscal year.
The company's revenue from operations also experienced a notable increase, reaching Rs 2,242 crore compared to Rs 1,911 crore in the previous year.
IndusInd Bank is expected to witness growth in net interest income (NII) and profit for the upcoming quarter. Furthermore, ITC's cigarette volume is projected to expand, indicating a positive outlook for the company in the current market environment.